Cargando…

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

BACKGROUND: Treatment effect is categorised into four classes by RECIST based on the evolution of the size of target lesions and the occurrence of new lesions, irrespective of tumour growth kinetics before treatment. This study aimed at evaluating the added value of tumour growth kinetics assessment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Tourneau, C, Servois, V, Diéras, V, Ollivier, L, Tresca, P, Paoletti, X
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305968/ https://www.ncbi.nlm.nih.gov/pubmed/22281665 http://dx.doi.org/10.1038/bjc.2012.10

Ejemplares similares

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2014)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
por: Vaflard, Pauline, et al.
Publicado: (2021)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?
por: Patil, V., et al.
Publicado: (2013)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling
por: Li, CH, et al.
Publicado: (2016)

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
por: Lamarca, Angela, et al.
Publicado: (2018)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
por: Toffart, Anne-Claire, et al.
Publicado: (2014)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment
por: Wesdorp, Nina J., et al.
Publicado: (2021)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yu, Hongli, et al.
Publicado: (2022)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
por: Le Tourneau, C, et al.
Publicado: (2014)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

Performance of NI-RADS on CECT Alone to Predict Recurrent Head and Neck Squamous Cell Carcinoma after Chemoradiotherapy: Added Value of RECIST 1.1.
por: Kumar, Ishan, et al.
Publicado: (2022)

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
por: Solis-Hernandez, Mª Pilar, et al.
Publicado: (2019)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Precision of manual two-dimensional segmentations of lung and liver metastases and its impact on tumour response assessment using RECIST 1.1
por: Cornelis, F. H., et al.
Publicado: (2017)

Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study
por: Loulergue, P, et al.
Publicado: (2011)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper
por: Fournier, Laure, et al.
Publicado: (2022)

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
por: Zheng, Bingjie, et al.
Publicado: (2021)

Imaging beyond RECIST: CT and MRI in molecular therapies
por: Diederich, Stefan
Publicado: (2012)

Response assessment in daily practice: RECIST and its modifications
por: Sohaib, Aslam
Publicado: (2014)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
por: Ko, Ching-Chung, et al.
Publicado: (2021)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien-Ju, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fbp43ufbcpmtvt57u1mh48sf6b